While there exists in-vivo biomarkers (e.g., beta amyloid and tau) that can serve as indicators of pathological progression toward AD, biomarker screenings are prohibitively expensive to scale if widely used among pre-symptomatic individuals in the outpatient setting1. Here, MAPT is linked to Alzheimer disease.